Gene TherapyDeveloping
Columbia Says Newer Gene Therapies Could Give Sickle Cell Patients More Options
Two NEJM-published experimental approaches show the sickle-cell gene therapy field moving from one breakthrough toward multiple strategies.
Why now
Columbia's update helps shift the sickle-cell gene therapy narrative from a single approved breakthrough to an emerging field of distinct strategies, risks, and access tradeoffs.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 27, 2026